CXCR1 and melanoma: A currently recruiting Phase I clinical trial (NCT03161431) will treat participants with melanoma for 21 days with SX-682, a CXCR1/2 inhibitor, as a monotherapy - then with pembrolizumab, an FDA approved immunotherapy for melanoma.